The recent use of innovative oral direct factor Xa and thrombin inhibitors represents a compelling approach to evaluate the advantages and disadvantages of anticoagulant treatments in clinical studies including patients with PAH [59]. Here, F10 is linked to pulmonary arterial hypertension.